US protection ending in 2034: Heart and blood vessels
As of the edition of 20 October 2026, 24 drugs have US protection that ends in 2034 in heart and blood vessels; 13 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
24 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Belumosudil | Ends 2034 (patent) | Marketed | Sanofi | ROCK1, ROCK2 | 4 |
| Belzutifan | Ends 2034 (patent) | Marketed | Merck & Co. | EPAS1 | 1 |
| Cedazuridine | Ends 2034 (patent) | Marketed | Taiho | CDA | 1 |
| Ciltacabtagene autoleucel | Ends 2034 (reference-product exclusivity) | Marketed | Johnson & Johnson | TNFRSF17 | 0 |
| Deferasirox | Ends 2034 (patent) | Marketed | Novartis | 0 | |
| Enasidenib | Ends 2034 (patent) | Marketed | Bristol Myers Squibb | IDH2 | 1 |
| Faricimab | Ends 2034 (computed from the first US licence) | Marketed | Roche | ANGPT2, VEGFA | 1 |
| Inclisiran sodium | Ends 2034 (patent) | Marketed | Novartis | PCSK9 | 0 |
| Ledipasvir | Ends 2034 (patent) | Marketed | Gilead Sciences | 0 | |
| Mosunetuzumab | Ends 2034 (computed from the first US licence) | Marketed | Roche | CD3D, CD3E, CD3G | 0 |
| Palbociclib | Ends 2034 (patent) | Marketed | Pfizer | CDK4, CDK6 | 2 |
| Pegulicianine acetate | Ends 2034 (patent) | Marketed | Lumicell | 0 | |
| Relatlimab | Ends 2034 (computed from the first US licence) | Marketed | Bristol Myers Squibb | LAG3 | 1 |
| Riociguat | Ends 2034 (patent) | Marketed | Bayer | GUCY1A1, GUCY1A2, GUCY1B1 | 1 |
| Semaglutide | Ends 2034 (patent) | Marketed | Novo Nordisk | GLP1R | 0 |
| Sofosbuvir | Ends 2034 (patent) | Marketed | Gilead Sciences | 0 | |
| Stem bromelain | Ends 2034 (computed from the first US licence) | Marketed | Vericel | 0 | |
| Tazemetostat | Ends 2034 (patent) | Marketed | Ipsen | EZH2 | 2 |
| Teclistamab | Ends 2034 (computed from the first US licence) | Marketed | Johnson & Johnson | CD3D, CD3E, CD3G | 0 |
| Tipiracil | Ends 2034 (patent) | Marketed | Taiho | TYMP | 1 |
| Tremelimumab | Ends 2034 (computed from the first US licence) | Marketed | AstraZeneca | CTLA4 | 1 |
| Tucatinib | Ends 2034 (patent) | Marketed | Pfizer | ERBB2 | 0 |
| Ublituximab | Ends 2034 (computed from the first US licence) | Marketed | TG Therapeutics | MS4A1 | 2 |
| Vibegron | Ends 2034 (patent) | Marketed | Sumitomo Pharma | ADRB3 | 2 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2034 in heart and blood vessels
In the product13 of these 24 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.